The impact of single nucleotide polymorphisms on return-to-work after taxane-based chemotherapy in breast cancer

Cathrine F. Hjorth*, Per Damkier, Tore B. Stage, Søren Feddersen, Stephen Hamilton-Dutoit, Bent Ejlertsen, Timothy L. Lash, Henrik Bøggild, Henrik T. Sørensen, Deirdre Cronin-Fenton

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

30 Downloads (Pure)

Abstract

Purpose: Breast cancer treatment is associated with adverse effects, which may delay return-to-work. Single nucleotide polymorphisms (SNPs) may influence the risk and severity of treatment toxicities, which in turn could delay return-to-work. We examined the association of 26 SNPs with return-to-work in premenopausal women with breast cancer. Methods: Using Danish registries, we identified premenopausal women diagnosed with non-distant metastatic breast cancer during 2007‒2011, assigned adjuvant combination chemotherapy including cyclophosphamide and docetaxel. We genotyped 26 SNPs in 20 genes (ABCB1, ABCC2, ABCG2, CYP1A1, CYP1B1, CYP3A, CYP3A4, CYP3A5, GSTP1, SLCO1B1, SLCO1B3, ARHGEF10, EPHA4, EPHA5, EPHA6, EPHA8, ERCC1, ERCC2, FGD4 and TRPV1) using TaqMan assays. We computed the cumulative incidence of return-to-work (defined as 4 consecutive weeks of work) up to 10 years after surgery, treating death and retirement as competing events and fitted cause-specific Cox regression models to estimate crude hazard ratios (HRs) and 95% confidence intervals (CIs) of return-to-work. We also examined stable labor market attachment (defined as 12 consecutive weeks of work). Results: We included 1,964 women. No associations were found for 25 SNPs. The cumulative incidence of return-to-work varied by CYP3A5 rs776746 genotype. From 6 months to 10 years after surgery, return-to-work increased from 25 to 94% in wildtypes (n = 1600), from 17 to 94% in heterozygotes (n = 249), and from 7 to 82% in homozygotes (n = 15). The HR showed delayed return-to-work in CYP3A5 rs776746 homozygotes throughout follow-up (0.48, 95% CI 0.26, 0.86), compared with wildtypes. Estimates were similar for stable labor market attachment. Conclusion: Overall, the SNPs examined in the study did not influence return-to-work or stable labor market attachment after breast cancer in premenopausal women. Our findings did suggest that the outcomes were delayed in homozygote carriers of CYP3A5 rs776746, though the number of homozygotes was low.

Original languageEnglish
JournalCancer Chemotherapy and Pharmacology
Volume91
Issue number2
Pages (from-to)157-165
ISSN0344-5704
DOIs
Publication statusPublished - Feb 2023

Keywords

  • Breast neoplasms
  • Cohort study
  • Docetaxel
  • Return-to-work
  • Single nucleotide polymorphisms
  • Taxane
  • Humans
  • Genotype
  • Xeroderma Pigmentosum Group D Protein/genetics
  • Return to Work
  • Cytochrome P-450 CYP3A/genetics
  • Taxoids/therapeutic use
  • Female
  • Polymorphism, Single Nucleotide
  • Liver-Specific Organic Anion Transporter 1/genetics
  • Breast Neoplasms/drug therapy
  • Microfilament Proteins/genetics

Fingerprint

Dive into the research topics of 'The impact of single nucleotide polymorphisms on return-to-work after taxane-based chemotherapy in breast cancer'. Together they form a unique fingerprint.

Cite this